1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2022, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 50, 44, 8, 120, 49 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 8 molecules, respectively.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hepatitis B - Overview
- Hepatitis B - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hepatitis B - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis B - Companies Involved in Therapeutics Development
- Hepatitis B - Drug Profiles
- Hepatitis B - Dormant Projects
- Hepatitis B - Discontinued Products
- Hepatitis B - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hepatitis B, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hepatitis B - Dormant Projects, 2022
- Hepatitis B - Discontinued Products, 2022
- Number of Products under Development for Hepatitis B, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abhelix LLC
- Achelois Cell Therapy
- Ai-biopharma SAS
- AiCuris Anti-infective Cures AG
- Albireo Pharma Inc
- Aligos Therapeutics Inc
- AlloVir Inc
- AlphaMab Co Ltd
- Alphamab Oncology
- Altimmune Inc
- Ancora Biotech LLC
- Antios Therapeutics Inc
- APITBIO Co Ltd
- Apros Therapeutics Inc
- Arcturus Therapeutics Holdings Inc
- Ascendo Biotechnology Inc
- Ascentage Pharma Group International
- Ascletis Pharma Inc
- Assembly Biosciences Inc
- AstriVax NV
- Aucta Pharmaceuticals LLC
- Auro Vaccines LLC
- Avalia Immunotherapies Ltd
- Beam Therapeutics Inc
- Beijing Advaccine Biotechnology Company Ltd
- Beijing Junke Huayuan Pharmaceutical Technology Co Ltd
- Beijing Kawin Technology Share-Holding Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Benitec Biopharma Inc
- Biological E Ltd
- Biomics Biopharma Ltd
- BioNet-Asia Co Ltd
- Biotron Ltd
- Bluejay Therapeutics Inc
- Bolder Biotechnology Inc
- Bonac Corp
- Brandenburg Antiinfektiva GmbH
- Bukwang Pharmaceutical Co Ltd
- CaroGen Corp
- Casterbridge Pharmaceuticals Inc
- CHA Vaccine Institute Co Ltd
- Chengdu Hyperway Pharmaceutical Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Chongqing Jiachen Biotechnology Ltd
- Chongqing Zhifei Biological Products Co Ltd
- Cinkate Corp
- ClearB Therapeutics Inc
- CN Bio Innovations Ltd
- Cocrystal Pharma Inc
- Collaborations Pharmaceuticals Inc
- ConserV Bioscience Ltd
- Curigin Co Ltd
- CyTuVax BV
- DelSiTech Ltd
- Dicerna Pharmaceuticals Inc
- Dong-A ST Co Ltd
- Door Pharmaceuticals LLC
- Drug Farm Inc
- Emergex Vaccines Holding Ltd
- Enanta Pharmaceuticals Inc
- Enochian Biosciences Inc
- Enyo Pharma SA
- Escient Pharmaceuticals Inc
- Etna Biotech Srl
- Evotec SE
- Evrys Bio
- Exavir Therapeutics Inc
- Excision BioTherapeutics Inc
- F. Hoffmann-La Roche Ltd
- FortuneRock (China) Ltd
- Fresh Tracks Therapeutics Inc
- Fujian Cosunter Pharmaceutical Co Ltd
- GemVax & KAEL Co Ltd
- GeneCure Biotechnologies LLC
- GeneLancet Biosciences Inc
- GeneScience Pharmaceuticals Co Ltd
- GeoVax Labs Inc
- Gilead Sciences Inc
- Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
- Globeimmune Inc
- GNI Group Ltd
- Golden Biotechnology Corp
- Grifols SA
- GSK plc
- Guangdong East Sunshine Pharmaceutical Co Ltd
- Guangxi Hebabiz Pharmaceutical Co Ltd
- Guangzhou Henovcom Bioscience Co Ltd
- Guangzhou Lupeng Pharmaceutical Co Ltd
- Guangzhou Yipinhong Pharmaceutical Co Ltd
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- HEC Pharma Co Ltd
- Henan Genuine Biotech Co Ltd
- Hepagene Therapeutics Shanghai Inc
- Hepion Pharmaceuticals Inc
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- ImmuneMed Inc
- Immunocore Limited
- Indaptus Therapeutics Inc
- Inovio Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- IRBM Science Park SpA
- ISA Pharmaceuticals BV
- ISR Immune System Regulation Holding AB
- Jeil Pharmaceutical Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Kainos Medicine Inc
- Kyung Dong Co Ltd
- LG Chem Ltd
- Ligand Pharmaceuticals Inc
- Lion TCR Pte Ltd
- Max Biopharma Inc
- Maxwell Biosciences Inc
- Microbiotix Inc
- Nanjing Yuandasai Weixin Biomedical Co Ltd
- Novo Medi Sciences Pvt Ltd
- Nucorion Pharmaceuticals Inc
- OliX Pharmaceuticals Inc
- Oncolys BioPharma Inc
- Palisades Therapeutics
- Palo Alto pharmaceuticals Inc
- PeLeMed Co Ltd
- PharmaEssentia Corp
- Prazer Therapeutics
- Precigen Inc
- Precision Biosciences Inc
- Profarma
- Prosit Sole Biotechnology (Beijing) Co Ltd
- Protheragen Inc
- Qilu Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Regulus Therapeutics Inc
- Replicor Inc
- Resonance Health Ltd
- REYON Pharmaceutical Co Ltd
- Rodos BioTarget GmbH
- Samjin Pharm Co Ltd
- SCG Cell Therapy Pte Ltd
- Sclnow Biotechnology Co Ltd
- SFA Therapeutics Inc
- Shanghai Ark Biopharmaceutical Co Ltd
- Shanghai Changsen Pharmaceutical Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai HEP Pharmaceutical Co Ltd
- Shanghai Jinwei Biotechnology Co Ltd
- Shanghai Zhimeng Biopharma Inc
- Shantha Biotechnics Pvt Ltd
- Shenzhen BinDeBio Ltd
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Silverback Therapeutics Inc
- Sinovac Biotech Ltd
- Sirnaomics Ltd
- SL VaxiGen Inc
- SQZ Biotechnologies Co
- Staidson BioPharma Inc
- Statera Biopharma Inc
- Suzhou Ribo Life Sciences Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Svenska Vaccinfabriken Produktion AB
- Taiga Biotechnologies Inc
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tekmira Pharmaceuticals Corporation
- Tetranov International Inc
- Tevogen Bio Inc
- Theravectys SA
- ToolGen Inc
- Transgene SA
- UBI Pharma Inc
- Vaccitech Plc
- Vaxart Inc
- Vaxine Pty Ltd
- VBI Vaccines Inc
- Vir Biotechnology Inc
- Viravaxx AG
- Viriom Inc
- Virion Therapeutics LLC
- Virocovax
- ViroStatics SRL
- VLP Biotech Inc
- Xi'an Xintong Pharmaceutical Research Co Ltd
- Xi'An Yufan Biotechnology Co Ltd
- Yangshengtang Co Ltd
- Yisheng Biopharma Co Ltd
- Zelluna Immunotherapy AS
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
